New York (HedgeCo.net) – With one big merger in the works but far from a done deal, the pharmaceutical sector is drawing a lot of attention from hedge funds. In the latest 13F filings hedge fund luminaries like David Tepper’s Appaloosa Management and John Paulson’s Paulson & Co both revealed positions in large pharmaceutical companies. For Tepper his position is in Mylan (NYSE: MYL) which is in merger talks with Perrigo (NYSE: PRGO). Paulson’s 13F revealed a new position in Teva Pharmaceuticals (NYSE: TEVA).

In addition to Tepper and Paulson’s pharma purchases, Kyle Bass’ Hayman Capital, Dan Loeb’s Third Point and Eric Mindich’s Eton Park fund all opened new positions on Perrigo.

Another stock that was added by both Paulson and Mindich as well as Paul Tudor Jones and his Tudor Investment Corp was semiconductor manufacturer Broadcom (Nasdaq: BRCM). Among the stocks getting dumped by hedge funds were Liberty Ventures (Nasdaq: LVNTA), IBM (NYSE: IBM) and Micron Technology (Nasdaq: MU).

Rick Pendergraft
Research Analyst
HedgeCoVest